|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Vigil Neuroscience, Inc. (VIGL) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,270,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vigil Neuroscience is a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Co.'s key candidate, VGL101, is a fully human monoclonal antibody that is designed to activate Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Co. is also developing a small molecule TREM2 agonist for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. The initial focus of Co.'s small molecule TREM2 agonist program is for the treatment of Alzheimer's disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
4,000 |
4,000 |
57,695 |
| Total Buy Value |
$0 |
$15,000 |
$15,000 |
$181,552 |
| Total People Bought |
0 |
1 |
1 |
5 |
| Total Buy Transactions |
0 |
1 |
1 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
300 |
| Total Sell Value |
$0 |
$0 |
$0 |
$4,200 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maravic Magovcevic Ivana |
President and CEO |
• • – |
2023-11-20 |
4 |
B |
$3.75 |
$15,000 |
D/D |
4,000 |
207,687 |
0.01 |
- |
|
| Papapetropoulos Spyridon |
Chief Medical Officer |
• – – |
2022-11-18 |
4 |
AS |
$14.00 |
$4,200 |
D/D |
(300) |
4,000 |
|
- |
|
| Papapetropoulos Spyridon |
Chief Medical Officer |
• – – |
2022-11-18 |
4 |
OE |
$1.89 |
$567 |
D/D |
300 |
4,300 |
|
- |
|
| Thorp Clay |
Director |
– • – |
2022-05-17 |
4 |
B |
$2.97 |
$44,189 |
I/I |
14,893 |
1,556,030 |
2.1 |
- |
|
| Thorp Clay |
Director |
– • – |
2022-05-16 |
4 |
B |
$2.76 |
$60,221 |
I/I |
21,802 |
1,541,137 |
2.1 |
- |
|
| Maravic Magovcevic Ivana |
President and CEO |
• • – |
2022-05-03 |
4 |
B |
$3.94 |
$3,940 |
D/D |
1,000 |
203,687 |
2.73 |
- |
|
| Verni Christopher |
General Counsel |
• – – |
2022-05-03 |
4 |
B |
$3.77 |
$15,074 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
| Papapetropoulos Spyridon |
Chief Medical Officer |
• – – |
2022-05-03 |
4 |
B |
$3.40 |
$13,591 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
| Ziolkowski Jennifer Lynn |
Chief Financial Officer |
• – – |
2022-05-03 |
4 |
B |
$3.77 |
$15,098 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
| Maravic Magovcevic Ivana |
President and CEO |
• • – |
2022-05-02 |
4 |
B |
$3.61 |
$14,439 |
D/D |
4,000 |
202,687 |
2.81 |
- |
|
| Thorp Clay |
Director |
– • – |
2022-03-28 |
4 |
B |
$7.20 |
$21,604 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| Cormorant Private Healthcare Fund Iv Lp |
Former 10% Owner |
– – – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
616,786 |
616,786 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,206,281 |
3,206,281 |
|
- |
|
| Vida Ventures Iii-A, L.p. |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$14.00 |
$23,450,000 |
I/I |
1,675,000 |
11,536 |
1.5 |
- |
|
| Vida Ventures Iii-A, L.p. |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,340,929 |
7,684 |
|
- |
|
| Vitorovic Stefan |
Director |
– • – |
2022-01-11 |
4 |
B |
$14.00 |
$23,450,000 |
I/I |
1,675,000 |
11,536 |
2.1 |
- |
|
| Vitorovic Stefan |
Director |
– • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,340,929 |
7,684 |
|
- |
|
| Thorp Clay |
Director |
– • – |
2022-01-11 |
4 |
B |
$14.00 |
$3,710,000 |
I/I |
265,000 |
1,519,335 |
2.1 |
- |
|
| Thorp Clay |
Director |
– • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
1,254,335 |
1,254,335 |
|
- |
|
| Booth Bruce |
Director |
– • – |
2022-01-11 |
4 |
B |
$14.00 |
$7,490,000 |
I/I |
535,000 |
4,808,896 |
2.1 |
- |
|
| Booth Bruce |
Director |
– • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,859,498 |
1,027,978 |
|
- |
|
| Rubin Michael P. |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$14.00 |
$4,970,000 |
I/I |
355,000 |
1,382,978 |
1.5 |
- |
|
| Rubin Michael P. |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,859,498 |
1,027,978 |
|
- |
|
| Alexandria Venture Investments, Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
192,973 |
192,973 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$14.00 |
$7,490,000 |
I/I |
535,000 |
4,808,896 |
1.5 |
- |
|
26 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
